Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys

Jes Gerlach, Daniel Casey

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

1. 1. Nine Cebus monkeys, 6 with mild spontaneous oral dyskinesia (tongue protrusions), were tested with two dopamine D2 antagonists, remoxipride (a new substituted benzamide) and haloperidol, and witn two dopamine agonists, methylphenidate and apomorphine. 2. 2. Remoxipride 4 and 8 mg kg and haloperidol 0.01 and 0.02 mg kg given alone induced identical dystonic-dyskinetic syndromes. 3. 3. Methylphenidate 0.5 mg kg caused increased arousal, but reduced oral dyskinesia, while apomorphine 0.25 mg kg slightly increased arousal and induced/aggravated oral dyskinesia. 4. 4. Remoxipride 2 and 4 mg kg and haloperidol 0.005 and 0.01 mg kg equally antagonized the methylphenidate- and apomorphine-induced arousal, but not oral dyskinesia. 5. 5. Marked sedation was seen when apomorphine was given together with either D2 receptor antagonists. 6. 6. It is concluded that remoxipride and haloperidol have a similar qualitative effect in motor behavior in Cebus monkeys, but the quantitative difference between the dystonia-inducing dose levels of the two drugs compared with the antipsychotic dose levels (estimated from clinical studies) suggests that remoxipride may cause relatively few extrapyramidal side-effects in human.

Original languageEnglish (US)
Pages (from-to)103-112
Number of pages10
JournalProgress in Neuropsychopharmacology and Biological Psychiatry
Volume14
Issue number1
DOIs
StatePublished - 1990

Fingerprint

Remoxipride
Cebus
Haloperidol
Apomorphine
Haplorhini
Movement Disorders
Methylphenidate
Arousal
Dystonia
Dopamine Agonists
Tongue
Antipsychotic Agents
Pharmaceutical Preparations

Keywords

  • apomorphine
  • arousal
  • dyskinesia
  • dystonia
  • haloperidol
  • methylphenidate
  • monkey
  • remoxipride

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys. / Gerlach, Jes; Casey, Daniel.

In: Progress in Neuropsychopharmacology and Biological Psychiatry, Vol. 14, No. 1, 1990, p. 103-112.

Research output: Contribution to journalArticle

@article{a6b9e6e2eb3b46509f95b3a0db66d6df,
title = "Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys",
abstract = "1. 1. Nine Cebus monkeys, 6 with mild spontaneous oral dyskinesia (tongue protrusions), were tested with two dopamine D2 antagonists, remoxipride (a new substituted benzamide) and haloperidol, and witn two dopamine agonists, methylphenidate and apomorphine. 2. 2. Remoxipride 4 and 8 mg kg and haloperidol 0.01 and 0.02 mg kg given alone induced identical dystonic-dyskinetic syndromes. 3. 3. Methylphenidate 0.5 mg kg caused increased arousal, but reduced oral dyskinesia, while apomorphine 0.25 mg kg slightly increased arousal and induced/aggravated oral dyskinesia. 4. 4. Remoxipride 2 and 4 mg kg and haloperidol 0.005 and 0.01 mg kg equally antagonized the methylphenidate- and apomorphine-induced arousal, but not oral dyskinesia. 5. 5. Marked sedation was seen when apomorphine was given together with either D2 receptor antagonists. 6. 6. It is concluded that remoxipride and haloperidol have a similar qualitative effect in motor behavior in Cebus monkeys, but the quantitative difference between the dystonia-inducing dose levels of the two drugs compared with the antipsychotic dose levels (estimated from clinical studies) suggests that remoxipride may cause relatively few extrapyramidal side-effects in human.",
keywords = "apomorphine, arousal, dyskinesia, dystonia, haloperidol, methylphenidate, monkey, remoxipride",
author = "Jes Gerlach and Daniel Casey",
year = "1990",
doi = "10.1016/0278-5846(90)90068-R",
language = "English (US)",
volume = "14",
pages = "103--112",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys

AU - Gerlach, Jes

AU - Casey, Daniel

PY - 1990

Y1 - 1990

N2 - 1. 1. Nine Cebus monkeys, 6 with mild spontaneous oral dyskinesia (tongue protrusions), were tested with two dopamine D2 antagonists, remoxipride (a new substituted benzamide) and haloperidol, and witn two dopamine agonists, methylphenidate and apomorphine. 2. 2. Remoxipride 4 and 8 mg kg and haloperidol 0.01 and 0.02 mg kg given alone induced identical dystonic-dyskinetic syndromes. 3. 3. Methylphenidate 0.5 mg kg caused increased arousal, but reduced oral dyskinesia, while apomorphine 0.25 mg kg slightly increased arousal and induced/aggravated oral dyskinesia. 4. 4. Remoxipride 2 and 4 mg kg and haloperidol 0.005 and 0.01 mg kg equally antagonized the methylphenidate- and apomorphine-induced arousal, but not oral dyskinesia. 5. 5. Marked sedation was seen when apomorphine was given together with either D2 receptor antagonists. 6. 6. It is concluded that remoxipride and haloperidol have a similar qualitative effect in motor behavior in Cebus monkeys, but the quantitative difference between the dystonia-inducing dose levels of the two drugs compared with the antipsychotic dose levels (estimated from clinical studies) suggests that remoxipride may cause relatively few extrapyramidal side-effects in human.

AB - 1. 1. Nine Cebus monkeys, 6 with mild spontaneous oral dyskinesia (tongue protrusions), were tested with two dopamine D2 antagonists, remoxipride (a new substituted benzamide) and haloperidol, and witn two dopamine agonists, methylphenidate and apomorphine. 2. 2. Remoxipride 4 and 8 mg kg and haloperidol 0.01 and 0.02 mg kg given alone induced identical dystonic-dyskinetic syndromes. 3. 3. Methylphenidate 0.5 mg kg caused increased arousal, but reduced oral dyskinesia, while apomorphine 0.25 mg kg slightly increased arousal and induced/aggravated oral dyskinesia. 4. 4. Remoxipride 2 and 4 mg kg and haloperidol 0.005 and 0.01 mg kg equally antagonized the methylphenidate- and apomorphine-induced arousal, but not oral dyskinesia. 5. 5. Marked sedation was seen when apomorphine was given together with either D2 receptor antagonists. 6. 6. It is concluded that remoxipride and haloperidol have a similar qualitative effect in motor behavior in Cebus monkeys, but the quantitative difference between the dystonia-inducing dose levels of the two drugs compared with the antipsychotic dose levels (estimated from clinical studies) suggests that remoxipride may cause relatively few extrapyramidal side-effects in human.

KW - apomorphine

KW - arousal

KW - dyskinesia

KW - dystonia

KW - haloperidol

KW - methylphenidate

KW - monkey

KW - remoxipride

UR - http://www.scopus.com/inward/record.url?scp=0025058679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025058679&partnerID=8YFLogxK

U2 - 10.1016/0278-5846(90)90068-R

DO - 10.1016/0278-5846(90)90068-R

M3 - Article

C2 - 1967845

AN - SCOPUS:0025058679

VL - 14

SP - 103

EP - 112

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -